Peter Dorfmüller

Peter Dorfmüller

Auto-generated profile, based on publicly available information

Peter Dorfmüller

12University Giessen and Marburg Lung Centre (UGMLC), Institute for Lung Health (ILH), Giessen, German Centre for Lung Research (DZL Standort Giessen), Giessen, Germany

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2019 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
MHMarc Humbert
Marc Humbert
Christophe GuignabertChristophe Guignabert
Christophe Guignabert
SBSébastien Bonnet
Sébastien Bonnet
PDPeter Dorfmüller
Peter Dorfmüller
JKJames R. Klinger
James R. Klinger
MRMarlene Rabinovitch
Marlene Rabinovitch
Clinical and translational research has played a major role in advancing our understanding of pulmonary hypertension (PH), including pulmonary arterial hypertension and other forms of PH with severe vascular remodelling (e.g. chronic thromboembolic PH and pulmonary veno-occlusive disease). However, PH remains an incurable condition with a high mortality rate, underscoring the need for a better transfer of novel scientific knowledge into healthcare interventions. Herein, we review recent findings in pathology (with the questioning of the strict morphological categorisation of various forms of PH into pre- or post-capillary involvement of pulmonary vessels) and cellular mechanisms contributing to the onset and progression of pulmonary vascular remodelling associated with various forms of PH. We also discuss ways to improve management and to support and optimise drug development in this research field.

17 March 2015 in Circulation
Verified
Journal Article
Closed access
BRBenoît Ranchoux
Benoît Ranchoux
Fabrice AntignyFabrice Antigny
Fabrice Antigny
CRCatherine Rucker-Martin
Catherine Rucker-Martin
AHAurélie Hautefort
Aurélie Hautefort
CPChristine Péchoux
Christine Péchoux
FPFrederic Perros
Frederic Perros
Background—: The vascular remodeling responsible for pulmonary arterial hypertension (PAH) involves predominantly the accumulation of α-smooth muscle actin–expressing mesenchymal-like cells in obstructive pulmonary vascular lesions. Endothelial-to-mesenchymal transition (EndoMT) may be a source of those α-smooth muscle actin–expressing cells. Methods and Results—: In situ evidence of EndoMT in human PAH was obtained by using confocal microscopy of multiple fluorescent stainings at the arterial level, and by using transmission electron microscopy and correlative light and electron microscopy at the ultrastructural level. Findings were confirmed by in vitro analyses of human PAH and control cultured pulmonary artery endothelial cells. In addition, the mRNA and protein signature of EndoMT was recognized at the arterial and lung level by quantitative real-time polymerase chain reaction and Western blot analyses. We confirmed our human observations in established animal models of pulmonary hypertension (monocrotaline and SuHx). After establishing the first genetically modified rat model linked to BMPR2 mutations (BMPR2 Δ140Ex1/+ rats), we demonstrated that EndoMT is linked to alterations in signaling of BMPR2, a gene that is mutated in 70% of cases of familial PAH and in 10% to 40% of cases of idiopathic PAH. We identified molecular actors of this pathological transition, including twist overexpression and vimentin phosphorylation. We demonstrated that rapamycin partially reversed the protein expression patterns of EndoMT, improved experimental PAH, and decreased the migration of human pulmonary artery endothelial cells, providing the proof of concept that EndoMT is druggable. Conclusions—: EndoMT is linked to alterations in BPMR2 signaling and is involved in the occlusive vas cular remodeling of PAH, findings that may have therapeutic implications.

1 December 2013 in JACC
Verified
Journal Article
Closed access
RTRubin M. Tuder
Rubin M. Tuder
SAStephen L. Archer
Stephen L. Archer
PDPeter Dorfmüller
Peter Dorfmüller
SESerpil C. Erzurum
Serpil C. Erzurum
Christophe GuignabertChristophe Guignabert
Christophe Guignabert
NMNicholas W. Morrell
Nicholas W. Morrell

1 August 2003 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
PDP. Dorfmüller
P. Dorfmüller
FPFrederic Perros
Frederic Perros
KBKarl Balabanian
Karl Balabanian
MHM. Humbert
M. Humbert
Inflammatory mechanisms appear to play a significant role in some types of pulmonary hypertension (PH), including monocrotaline-induced PH in rats and pulmonary arterial hypertension of various origins in humans, such as connective tissue diseases (scleroderma, systemic lupus erythematosus, mixed connective disease), human immunodeficiency virus infection, or plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal (M) protein and skin changes (POEMS) syndrome.Interestingly, some patients with severe pulmonary arterial hypertension associated with systemic lupus erythematosus have experienced significant improvements with immunosuppressive therapy, emphasising the relevance of inflammation in a subset of patients presenting with PH. Patients with primary PH (PPH) also have some immunological disturbances, suggesting a possible role for inflammation in the pathophysiology of this disease. A subset of PPH patients have been shown to have circulating autoantibodies, including antinuclear antibodies, as well as elevated circulating levels of the pro-infammatory cytokines, interleukins ‐1 and ‐6. Lung histology has also revealed inflammatory infiltrates in the range of plexiform lesions in patients displaying severe PPH, as well as an increased expression of the chemokines regulated upon activation, normal T‐cell expressed and secreted (RANTES) and fractalkine.Further analysis of the role of inflammatory mechanisms is necessary to understand whether this component of the disease is relevant to its pathophysiology.

1 July 2008 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
FPFrederic Perros
Frederic Perros
David MontaniDavid Montani
David Montani
PDPeter Dorfmüller
Peter Dorfmüller
IDIngrid Durand-Gasselin
Ingrid Durand-Gasselin
CTColas Tcherakian
Colas Tcherakian
MHMarc Humbert
Marc Humbert
Rationale: Platelet-derived growth factor (PDGF) promotes the proliferation and migration of pulmonary artery smooth muscle cells (PASMCs), and may play a role in the progression of pulmonary arterial hypertension (PAH), a condition characterized by proliferation of PASMCs resulting in the obstruction of small pulmonary arteries. Objectives: To analyze the expression and pathogenic role of PDGF in idiopathic PAH. Methods: PDGF and PDGF receptor mRNA expression was studied by real-time reverse transcription–polymerase chain reaction performed on laser capture microdissected pulmonary arteries from patients undergoing lung transplantation for idiopathic PAH. Immunohistochemistry was used to localize PDGF, PDGF receptors, and phosphorylated PDGFR-β. The effects of imatinib on PDGF-B–induced proliferation and chemotaxis were tested on human PASMCs. Measurements and Main Results: PDGF-A, PDGF-B, PDGFR-α, and PDGFR-β mRNA expression was increased in small pulmonary arteries from patients displaying idiopathic PAH, as compared with control subjects. Western blot analysis revealed a significant increase in protein expression of PDGFR-β in PAH lungs, as compared with control lungs. In small remodeled pulmonary arteries, PDGF-A and PDGF-B mainly localized to PASMCs and endothelial cells (perivascular inflammatory infiltrates, when present, showed intensive staining), PDGFR-α and PDGFR-β mainly stained PASMCs and to a lesser extent endothelial cells. Proliferating pulmonary vascular lesions stained phosphorylated PDGFR-β. PDGF-BB–induced proliferation and migration of PASMCs were inhibited by imatinib. This effect was not due to PASMC apoptosis. Conclusions: PDGF may play an important role in human PAH. Novel therapeutic strategies targeting the PDGF pathway should be tested in clinical trials.

29 March 2017 in European Respiratory Review
Verified
Journal Article
Open access
PDF file
GSGérald Simonneau
Gérald Simonneau
Adam TorbickiAdam Torbicki
Adam Torbicki
PDPeter Dorfmüller
Peter Dorfmüller
NKNick Kim
Nick Kim
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, progressive pulmonary vascular disease that is usually a consequence of prior acute pulmonary embolism. CTEPH usually begins with persistent obstruction of large and/or middle-sized pulmonary arteries by organised thrombi. Failure of thrombi to resolve may be related to abnormal fibrinolysis or underlying haematological or autoimmune disorders. It is now known that small-vessel abnormalities also contribute to haemodynamic compromise, functional impairment and disease progression in CTEPH. Small-vessel disease can occur in obstructed areas, possibly triggered by unresolved thrombotic material, and downstream from occlusions, possibly because of excessive collateral blood supply from high-pressure bronchial and systemic arteries. The molecular processes underlying small-vessel disease are not completely understood and further research is needed in this area. The degree of small-vessel disease has a substantial impact on the severity of CTEPH and postsurgical outcomes. Interventional and medical treatment of CTEPH should aim to restore normal flow distribution within the pulmonary vasculature, unload the right ventricle and prevent or treat small-vessel disease. It requires early, reliable identification of patients with CTEPH and use of optimal treatment modalities in expert centres.